MSH6 and endometrial endometrioid carcinoma: To validate the functional role of GSDMD in pyroptosis, we established patient-derived organoids (PDOs) from a 57-year-old female diagnosed with FIGO 2023 stage IIC MMRd-type endometrioid endometrial carcinoma (ER/PR/MLH1/PMS2 negative; MSH2/MSH6 positive; partial p53 positivity; Ki-67 ~90%; germline BRCA1/2 wild-type).